110 likes | 182 Views
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director Gondriep@kncvtbc.nl. KNCV Tuberculosis Foundation. Established in 1903 in the Netherlands Mission
E N D
Innovation in TB control: what’s in it for the field? Peter C.F.M. Gondrie, MD, MPH Executive Director Gondriep@kncvtbc.nl
KNCV Tuberculosis Foundation • Established in 1903 in the Netherlands • Mission • Global elimination of tuberculosis through the development and implementation of effective, efficient and sustainable tuberculosis control strategies • Core activities - Program support - Human resource development - Policy development - Epidemiological and operational research - Strengthening awareness - Fundraising
Active in more than 40 countries • Active in more than 40 countries; approximately three million patients are traced annually worldwide: more than 85% of these recover
ACTUAL DATA TUBERCULOSIS • 9.4 MILLION INCIDENT CASES • 1.8 MILLION DEATHS (500,000 CO-INFECTED) • 440.000 MDR-TB CASES • Case Detection Rate N+: 61% • Case Detection Rate MDR-TB: 7% • Treatment Success Rate N+: 87% • Treatment Success Rate MDR-TB: 60%
Recent Developments NEW DIAGNOSTICS • WHO endorsement of: a) new smear positive case definition b) reduced no. of sputum specimens examined by smear microscopy c) liquid culture, rapid speciation and DST d) line probe assays for rifampicine and INH resistance Several large-scale multi-country trials of new tools underway
Recent Developments NEW DRUGS • Clinical Development Phase 3: 1 product • Clinical Development Phase 2: 2 products • Discovery Phase 2 (optimization): 6 products • Discovery Phase 1 (identification): 11 products
Recent Developments NEW VACCINS Keeping the Pipeline filled More than 40 TB vaccine candidates in the preclinical TB vaccine pipeline Performing clinical trials • 6 TB vaccine candidates have entered Phase I (safety) clinical trials • 3TB vaccine candidates have entered Phase II (immunogenicity) trials • 1 TB vaccine candidate has entered Phase III (efficacy) clinical trials
Requirements from the field • RESPONDING TO IDENTIFIED NEEDS • EFFECTIVE • AFFORDABLE • CONTRIBUTING TOWARDS EQUITY • HUMAN RESOURCES FRIENDLY
Mohandas Gandhi The difference between what we do and what we are capable of doing would suffice to solve most of the world’s problems